Last checked at 24 Jan 2019 07:00
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR notification
Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces that options to subscribe for an aggregate 321,100 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted, on 23 January 2019, to Matthew Hall, Chief Financial Officer and Andrew Stewart, General Counsel & Company Secretary as follows:
Name | Position | Number of Share Options Awarded | Exercise price per Share |
Matthew Hall | Chief Financial Officer | 160,550 | £1.09 |
Andrew Stewart | General Counsel & Company Secretary | 160,550 | £1.09 |
.
The Options have been granted under the Company's 2016 Share Option Plan and have an exercise price of £1.09, being the closing price of shares at 22 January 2019.
Other than the grant of the Options, neither Mr Hall, Mr Stewart or their respective connected persons have any beneficial interest in the Ordinary Shares of the Company.
This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| 1) Matthew Hall 2) Andrew Stewart | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| 1) Chief Financial Officer 2) General Counsel & Company Secretary | |||
b)
| Initial notification /Amendment
| Initial notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Oncimmune Holdings plc | |||
b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each
| |||
Identification code | ISIN: GB00BYQ94H38 | ||||
b)
| Nature of the transaction
| Grant of options | |||
c)
| Price(s) and volume(s) | ||||
Price(s) | Volume(s) | ||||
1) £1.09 | 160,550 | ||||
2) £1.09 | 160,550 | ||||
d)
| Aggregated information | ||||
- Aggregated volume | 321,100 | ||||
- Price | £1.09 | ||||
e)
| Date of the transaction
| 22 January 2019 | |||
f)
| Place of the transaction
| Outside a trading venue | |||
For further information:
Oncimmune Holdings plc
Adam Hill, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, John Goold
+44 (0)20 3829 5000
Bryan, Garnier & Co Limited (Joint Broker)
Phil Walker, Dominic Wilson
+44 (0)20 7332 2500
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
Oncimmune@consilium-comms.com
+44 (0)20 3709 5708
About Oncimmune
Beating cancer, one test at a time
Oncimmune is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body's natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT®-Lung and EarlyCDT®-Liver. To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT®-Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered in Nottingham, UK with a CLIA lab in Kansas, US and offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
For more information, visit www.oncimmune.com